Share

    


Home / Search Results

Search Results

You searched for:

    Displaying results 1 - 20 of 35
  • 1
  • 2
  • »
Advanced Practice Providers (APPs), such as nurse practitioners and physician assistants, play a fundamental role within medical oncology departments and the care of patients with cancer.
This article explores Johns Hopkins University’s unique approach to recruiting specialists outside the field of oncology to participate in its virtual immune-related Toxicity Team.
I M M U N O - ONCOLOGY I N S T I T U T E ASSOCIATION OF COMMUNITY CANCER CENTERS To help community oncology programs and practices across the United States better integrate immunotherapies to treat cancer, the Association of Community Cancer Centers (ACCC) hosted a day-long, expert faculty-driven workshop with three Member Programs: Grand Valley Oncology in Grand Junction, …
Oncodermatology is a rapidly developing field that is attracting significant interest and generating new literature in the context of cancer treatment strategies.
The non-specific adverse events of immune-based therapies, which often mimic autoimmune disorders rather than traditional cytotoxic effects, pose a significant challenge to emergency medicine providers.
Caring for patients experiencing toxicities from treatment with immune checkpoint inhibitors (ICIs) requires multidisciplinary input and coordination. Rheumatologists evaluate and treat patients experiencing a wide variety of immune-related adverse events (irAEs), including inflammatory arthritis, sicca syndrome, polymyalgia rheumatica, myositis, vasculitis, and scleroderma. It’s important for rheumatologists …
With the rise of immunotherapies, it is critical to ensure patient safety, as the toxicity profiles of immunotherapy agents are vastly different from traditional cytotoxic chemotherapies.
Since the approval of the programmed death-1 (PD-1) inhibitors pembrolizumab and nivolumab for the treatment of metastatic melanoma in 2014, the oncology community has seen a tidal wave of new approvals and indications for immunotherapies to treat cancer.
Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.
In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.
In this newly published IO Whitepaper, we take a forward look at how the ACCC IO Institute meets the needs of the evolving multidisciplinary cancer care team and other interdisciplinary providers who may be involved in caring for patients treated with immunotherapies for cancer.
For perspective on the impact of COVID-19 on clinical trials research in the area of immunotherapy, ACCCBuzz spoke with Joanne Riemer, Research Oncology Nurse at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, Maryland. Joanne is a senior research oncology nurse in the Upper Aero-digestive Team. In January 2011, she was asked to work with the immunology group on …
This article explores how Jefferson Health is taking a unique approach to recruiting specialists outside the field of oncology to participate in an Immuno-oncology Working Group.
This article explores how Cleveland Clinic is taking a unique approach to recruiting specialists outside the field of oncology to participate in immunotherapy multispecialty immune-related adverse events (irAE) tumor boards.
As more patients are treated with single and combination immunotherapies for cancer, early identification and management of immune-related adverse events (irAEs) is critical to achieving desired outcomes with these new drugs. ACCCBuzz recently talked with Matthew R. Zibelman, MD, for perspective on irAE management in patients treated with immune checkpoint inhibitor therapy. Dr. Zibelman is a genitourinary …
In order to explore experiences and needs concerning cancer survivorship from both the provider and the patient perspectives, ACCC and NCCS partnered to field two online surveys to oncology providers and cancer survivors, respectively.
Our busy community practice first began treating patients with immunotherapy through participating in the original ipilimumab clinical trials. We quickly realized that this new treatment paradigm would require us to create and implement an effective screening and management tool for our immunooncology (IO) patient population.
Immune-related adverse events (irAEs) are extremely common in patients being treated with checkpoint inhibitors for advanced melanoma. The type, quality, and severity of these adverse events, however, varies by treatment regimen and by patient.
The ACCC Immuno-Oncology Institute developed a multidisciplinary curriculum workshop bringing together faculty experienced in delivery of immunotherapy with cancer program staff in the earlier stages of IO integration. Over the past two years, these IO Visiting Experts Programs were hosted by ACCC Cancer Program Members nation-wide.
Patients with complex medical needs, such as those with active autoimmune conditions, hepatitis B or C, and those receiving corticosteroids at baseline, may now receive these agents in the community. This raises important questions regarding safety, monitoring, and the likelihood of an anticancer response in these patients.
    Displaying results 1 - 20 of 35
  • 1
  • 2
  • »